BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed KRYS catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:c82b8cd4c50a3be6a155@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KRYS P1/P2 readout (est.): EMERALD-1
DESCRIPTION:A Study Comparing KB801 Verse Placebo in Patients With Stage 2 
 or 3 Neurotrophic Keratitis\nNCT06999733 | PHASE1/PHASE2 | RECRUITING | sp
 onsor: Krystal Biotech\, Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker KRYS (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT06999733\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06999733
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f05e339bbf3731124ed6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KRYS P3 readout (est.): IOLITE
DESCRIPTION:A Study Comparing KB803 and Matched Placebo in Patients With Dy
 strophic Epidermolysis Bullosa\nNCT07016750 | PHASE3 | RECRUITING | sponso
 r: Krystal Biotech\, Inc.\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nDate precision: month (shown on the first d
 ay)\nTicker KRYS (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT07016750\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07016750
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a7ab09b1a487c6b1c4fb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:KRYS P1/P2 readout (est.): KYANITE-1
DESCRIPTION:A Study Assessing KB707 for the Treatment of Advanced Solid Tum
 or Malignancies Affecting the Lungs\nNCT06228326 | PHASE1/PHASE2 | RECRUIT
 ING | sponsor: Krystal Biotech\, Inc.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker KRYS (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT06228326\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06228326
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
